In Vitro Activity of Twenty-Three Antimicrobials Against Yersinia pestis Strains

Goto, Shinichi; Tsuji, Akiyoshi; Murai, Teiko; Nishida, Motohiro; Tsukano, Hiroko; Watanabe, Haruo

doi:10.1007/bf02348758

Cited by 3 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study, the in vitro activities of 23 drugs against 22 strains of Y. pestis were determined in vitro. 6 In the present study, these results were extended using an in vivo murine Ypestis infection model.…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

Therapeutic Effect of Antimicrobial Drugs against Experimental Infections Due to Yersinia pestis in Mice

Goto

Tsuji

Murai

et al. 1998

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 51%

“…4,5 Previously, we determined the in vitro activity of 23 drugs against 22 strains of Y pestis and found potent in vitro activities of several fluoroquinotones against the test strains. 6 The present paper describes the in vivo activities of …”

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect of Antimicrobial Drugs against Experimental Infections Due to Yersinia pestis in Mice

Goto

Tsuji

Murai

et al. 1998

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

“…The cell cultures were then used for evaluating in MIC assays. In the preliminary experiment, we found that by using the cell density of 10 5 CFU/ml [36] we were unable to detect any bacterial growth after 48 hrs incubation at 27°C in 96-well polypropylene microtiter plates, even though no antibiotics were added in the medium. Thus, we raised the cell density by 100-fold (final cell concentration, 10 7 CFU/ml) for the MIC determination.…”

Section: Methodsmentioning

confidence: 95%

“…The KIM6+/pF1, pHF, pSA, pSF1, pSM, and control pY were determined for erythromycin and PMB MICs using the procedure as previously described with slight modifications [36] . Y. pestis strains KIM6+/pF1, pHF, pSA, pSF1, pSM, and pY were grown in BHI broth at 27°C for 18 hrs without shaking, since we found that shaking would result in serious cell agglutination for all these 6 strains (data not shown).…”

Section: Methodsmentioning

confidence: 99%

Vulnerabilities in Yersinia pestis caf Operon Are Unveiled by a Salmonella Vector

et al. 2012

View full text Add to dashboard Cite

During infection, Yersinia pestis uses its F1 capsule to enhance survival and cause virulence to mammalian host. Since F1 is produced in large quantities and secreted into the host tissues, it also serves as a major immune target. To hold this detrimental effect under proper control, Y. pestis expresses the caf operon (encoding the F1 capsule) in a temperature-dependent manner. However, additional properties of the caf operon limit its expression. By overexpressing the caf operon in wild-type Salmonella enterica serovar Typhimurium under a potent promoter, virulence of Salmonella was greatly attenuated both in vitro and in vivo. In contrast, expression of the caf operon under the regulation of its native promoter exhibited negligible impairment of Salmonellae virulence. In-depth investigation revealed all individual genes in the caf operon attenuated Salmonella when overexpressed. The deleterious effects of caf operon and the caf individual genes were further confirmed when they were overexpressed in Y. pestis KIM6+. This study suggests that by using a weak inducible promoter, the detrimental effects of the caf operon are minimally manifested in Y. pestis. Thus, through tight regulation of the caf operon, Y. pestis precisely balances its capsular anti-phagocytic properties with the detrimental effects of caf during interaction with mammalian host.

show abstract

“…In vitro, measurement of the minimum inhibitory concentration (MIC) in a microdilution assay that complied with the Clinical and Laboratory Standards Institute’s guidelines for the Enterobacteriaceae revealed that tetracyclines, fluoroquinolones, aminoglycosides, sulfonamides, and most of β-lactams are active against Y. pestis ; the MIC 90 ranged from below 0.125 mg/L to 4 mg/L ( Table 1 ) [ 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ]. However, few studies have determined the MICs in more than one strain, and most of the MIC assays were performed at Yersinia optimal growth temperature (28 °C)—a temperature at which the lipooligosaccharide’s structure is not the same as at 37 °C [ 72 ].…”

Section: Antimicrobial Chemotherapymentioning

confidence: 99%

Antibiotic Therapy of Plague: A Review

Sebbane

Lemaître

2021

Biomolecules

View full text Add to dashboard Cite

Plague—a deadly disease caused by the bacterium Yersinia pestis—is still an international public health concern. There are three main clinical forms: bubonic plague, septicemic plague, and pulmonary plague. In all three forms, the symptoms appear suddenly and progress very rapidly. Early antibiotic therapy is essential for countering the disease. Several classes of antibiotics (e.g., tetracyclines, fluoroquinolones, aminoglycosides, sulfonamides, chloramphenicol, rifamycin, and β-lactams) are active in vitro against the majority of Y. pestis strains and have demonstrated efficacy in various animal models. However, some discrepancies have been reported. Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. Concerns about the emergence of multidrug-resistant strains of Y. pestis have led to the development of new classes of antibiotics and other therapeutics (e.g., LpxC inhibitors, cationic peptides, antivirulence drugs, predatory bacteria, phages, immunotherapy, host-directed therapy, and nutritional immunity). It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.

show abstract

In Vitro Activity of Twenty-Three Antimicrobials Against Yersinia pestis Strains

Cited by 3 publications

References 3 publications

Therapeutic Effect of Antimicrobial Drugs against Experimental Infections Due to Yersinia pestis in Mice

Therapeutic Effect of Antimicrobial Drugs against Experimental Infections Due to Yersinia pestis in Mice

Vulnerabilities in Yersinia pestis caf Operon Are Unveiled by a Salmonella Vector

Antibiotic Therapy of Plague: A Review

Contact Info

Product

Resources

About